Chen et al. have reported that activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in HCC, and the combined administration of sorafenib and MK-2206 overcomes the resistance [9]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.